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Abstract 
Theranostic systems capable of delivering imaging and therapeutic agents at a specific target are the 
focus of intense research efforts in drug delivery. To overcome non-degradability and toxicity 
concerns of conventional theranostic systems, we formulated a novel thermo-responsive 
fluorescent polymer (TFP) and conjugated it on the surface of iron oxide magnetic nanoparticles 
(MNPs) for imaging and therapeutic applications in solid tumors. Methods: TFP-MNPs were 
synthesized by copolymerizing poly(N-isopropylacrylamide), allylamine and a biodegradable 
photoluminescent polymer, and conjugating it on MNPs via a free radical polymerization reaction. 
Physicochemical properties of the nanoparticles were characterized using Fourier transform 
infrared spectroscopy, dynamic light scattering, and vibrational sample magnetometry. Nanoparticle 
cytocompatibility, cellular uptake and cytotoxicity were evaluated using in vitro cell assays. Finally, in 
vivo imaging and therapeutic efficacy studies were performed in subcutaneous tumor xenograft 
mouse models. Results: TFP-MNPs of ~135 nm diameter and -31 mV ζ potential maintained 
colloidal stability and superparamagnetic properties. The TFP shell was thermo-responsive, 
fluorescent, degradable, and released doxorubicin in response to temperature changes. In vitro cell 
studies showed that TFP-MNPs were compatible to human dermal fibroblasts and prostate 
epithelial cells. These nanoparticles were also taken up by prostate and skin cancer cells in a 
dose-dependent manner and exhibited enhanced killing of tumor cells at 41°C. Preliminary in vivo 
studies showed theranostic capabilities of the nanoparticles with bright fluorescence, MRI signal, and 
therapeutic efficacy under magnetic targeting after systemic administration in tumor bearing mice. 
Conclusion: These results indicate the potential of TFP-MNPs as multifunctional theranostic 
nanoparticles for various biological applications, including solid cancer management. 
Key words: theranostic systems; thermo-responsive polymers; photoluminescent polymers; solid tumors; 
magnetic nanoparticles 
Introduction 
Theranostic drug delivery systems are attractive 
platforms comprising diagnostic and therapeutic 
agents for simultaneous imaging and therapy in a 
single setting. Theranostic systems can potentially 
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assist in non-invasive monitoring of both the disease 
progression and nanoparticle drug delivery route [1]. 
Stimuli-responsive polymers and imaging agents (e.g. 
quantum dots, organic dyes or iron oxide 
nanoparticles) are attractive candidates for 
formulating theranostic systems, as they can be 
tracked following administration and provide 
controlled drug release in response to external stimuli. 
However, these systems are limited by 
non-biodegradability of polymers and by toxicity, 
photobleaching and possible leaching-out of the 
imaging agents [2]. To overcome these limitations, 
biodegradable photoluminescent materials have been 
developed from diverse materials such as porous 
silicon nanostructures, conjugated polymeric 
nanoparticles containing π conjugated electron 
systems, and combinations of polyethylene glycol, 
citric acid, aliphatic diols and amino acid based 
polymers for in vivo biomedical applications such as 
tumor imaging and tracking the degradation progress 
of implanted scaffold materials [3-6]. The 
degradability of these polymers and the superior 
photoluminescent properties such as high quantum 
yield, photobleaching resistance, and tunable 
emission up to near infrared region, make them 
unique for trackable drug delivery systems. 
Moreover, these polymers have demonstrated 
excellent compatibility and imaging ability both in 
vitro [7] and in vivo [5]. 
Thermo-responsive polymers have long been 
studied for drug delivery applications due to their 
attractive temperature-dependent drug release 
behavior. Poly(N-isopropylacrylamide) (PNIPAAm) 
and its copolymers are the most commonly used 
thermo-responsive polymers for such applications [8, 
9]. PNIPAAm undergoes a reversible phase-transition 
at a characteristic lower critical solution temperature 
(LCST) of 32°C [10-12]. At temperatures below the 
LCST, the polymer becomes hydrophilic and swells 
by absorbing large quantities of water; whereas at 
temperatures higher than the LCST, the interactions 
among hydrophobic groups increase, causing the 
polymer to become hydrophobic by shrinking and 
releasing the payload. PNIPAAm is usually 
copolymerized with hydrophilic monomers such as 
acrylamide to increase the LCST above body 
temperature for controlled drug delivery applications 
as well as with monomers such as allylamine (AH) to 
provide amine functional groups for bioconjugation 
applications [13]. Despite PNIPAAm’s immense 
potential in the field of drug delivery and biomedical 
sciences, it suffers the disadvantage of 
non-degradability, which may cause inflammatory 
and toxic responses due to the prolonged presence of 
the polymer in the body [10, 11, 14]. This limitation 
has provided the motivation for several research 
groups to develop biodegradable and temperature- 
sensitive PNIPAAm-based copolymers for drug 
delivery applications [15-17]. 
In the current work, we have developed a 
copolymer of PNIPAAm, AH, and a previously 
developed water soluble biodegradable photolumi-
nescent polymer (WBPLP) [5] to form a novel 
thermo-responsive fluorescent polymer (TFP), and 
subsequently formulated the nanoparticles (TFP NPs). 
The unique combination of WBPLP and PNIPAAm 
may enable nanoparticle tracking in vivo using 
fluorescence imaging, while providing controlled and 
temperature-dependent release of the encapsulated 
payload. The presence of WBPLP in the copolymer 
may also elevate the LCST of the PNIPAAm due to 
added hydrophilic content in the polymer backbone, 
thus eliminating commonly used toxic acrylamide 
monomers to increase the LCST. 
Another aspect of our work was the utilization of 
superparamagnetic iron oxide nanoparticles as core 
materials to coat the TFP polymer on. Iron oxide 
magnetic nanoparticles (MNPs) are usually 10-100 nm 
in size and by virtue of their magnetic property can be 
recruited at a specific site in vivo. The superparama-
gnetic nature of iron oxide nanoparticles makes them 
efficient T2 weighted magnetic resonance imaging 
(MRI) contrast agents that can be applied as imaging 
probes for early tumor detection [18]. These attributes 
make MNPs potentially useful for tumor imaging as 
well as magnetic and image guided drug delivery [19, 
20]. This is highly beneficial in limiting the uptake of 
toxic chemotherapeutic molecules by healthy cells, 
thus improving drug delivery efficacy [21]. Despite 
the immense potential of MNPs for tumor diagnosis 
and therapy, there remain a limited number of 
MNPs-based formulations approved for clinical use 
[22], possibly due to their reactive surface mediated 
toxicity. The proposed TFP polymer coating on iron 
oxide nanoparticles may help alleviate iron oxide 
toxicity and make an improved magnetic nanoparticle 
system. In addition, the TFP would provide 
fluorescent signals for optical imaging, making a 
multi-modal imaging system for enhanced imaging 
and diagnosis. Thus, we investigated TFP-coated 
MNPs (TFP-MNPs) core-shell system for potential 
magnetic targeting, multi-modal (optical and MRI) 
imaging, and simulated magnetic hyperthermia 
applications, so that both diagnosis and treatment of 
the disease is possible in a single setting. 
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Materials and Methods 
Materials 
All chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO) and used without 
further modification. All cell lines were purchased 
from ATCC (Manassas, VA), and Dulbecco’s modified 
Eagle’s medium (DMEM), trypsin EDTA, fetal bovine 
serum (FBS), and penicillin-streptomycin were 
purchased from Invitrogen (Carlsbad, CA) and used 
for in vitro cell culture studies. 
Synthesis of fluorescent polymer 
WBPLP was synthesized following our 
previously developed protocols [5]. Briefly, equimolar 
ratios of citric acid and 1,8-octane diol were combined 
with L-cysteine, while keeping the L-cysteine to citric 
acid ratio at 0.8. The mixture was melted at 160°C for 
20 minutes, subsequently cooled to 140°C and reacted 
for an additional 75 minutes to form BPLP-Cysteine 
oligomers. The BPLP-Cysteine oligomers were 
collected via precipitation using a water/1-4 dioxane 
mixture and were later freeze dried and subsequently 
combined with polyethylene glycol and amino acids 
to form water soluble BPLP (WBPLP). 
Copolymerization of WBPLP and AH 
WBPLP was then conjugated with AH using 
carbodiimide chemistry [23]. In brief, WBPLP (45 mg) 
was dissolved in 2-(N-morpholino) ethanesulphonic 
acid (MES) buffer (5 ml), followed by the addition of 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-Hydroxy Succinimide (NHS) (1:1). After 
30 minutes of mixing on a rotator, AH (18.75 µl) was 
added and the reaction was continued for 12 hours at 
room temperature. The WBPLP-AH copolymer was 
then dialyzed using 500 Da molecular weight cut-off 
dialysis membranes (Spectrum Laboratories Inc, 
Rancho Dominguez, CA) for 24 hours to remove the 
unreacted chemicals. 
Synthesis of TFP NPs 
To generate TFP NPs, WBPLP-AH was then 
copolymerized with N-isopropylacrylamide 
(NIPAAm) by radical polymerization in the presence 
of a crosslinker. In brief, the purified WBPLP-AH 
solution (5 ml) and NIPAAm (45 mg) were dissolved 
in deionized (DI) water (25 ml). Crosslinker, 
N,N’-Methylenebisacryamide (BIS, 5.85 mg) and 
surfactant, sodium dodecyl sulphate (SDS, 17.4 mg) 
were added to the mixture, while continuously 
stirring for 30 minutes. Ammonium persulphate 
(APS, 52.48 mg) and tetramethylethylenediamine 
(TEMED, 69 µl) were then added to initiate the radical 
polymerization, and the reaction was stirred for 4 
hours under nitrogen at room temperature. The 
formed nanoparticle solution was dialyzed using 3500 
Da molecular weight cut-off dialysis membranes for 
24 hours to remove free surfactants and unreacted 
chemicals. 
Synthesis of TFP-MNPs 
TFP-MNPs were synthesized using silane- 
functionalized MNPs (silane-MNPs) as templates for 
TFP conjugation. Silane-MNPs were synthesized by 
dispersing MNPs in 99% ethanol by sonication (50 W, 
5 minutes), followed by the addition of acetic acid (2 
ml). After 5 minutes of further sonication, the reaction 
was transferred to a stir plate and vinyltrime-
thoxysilane (0.49 ml) was added. The reaction was 
carried out for 24 hours at room temperature. 
Silane-MNPs were then washed several times with 
99% ethanol and collected using a magnet. To prepare 
the TFP-MNPs, silane-MNPs (10 mg) were sonicated 
in DI water (25 ml) at 50 W for 10 minutes. The 
purified WBPLP-AH (100 mg), NIPAAm (45 mg), BIS 
(5.85 mg) and SDS (17.4 mg) were added to the 
reaction while sonicating. The reaction was then 
transferred to a stir plate, and APS (52.48 mg) and 
TEMED (69 µl) were added to the reaction with 
vigorous stirring. The reaction was carried out under 
nitrogen for 4 hours at room temperature. The 
TFP-MNPs were collected by a magnet and washed 
several times with DI water to remove surfactants and 
unreacted chemicals. 
Physicochemical characterization 
Particle size, morphology, polydispersity index 
(PDI), and surface charge (ζ potential) were evaluated 
using transmission electron microscopy (TEM; 
Technai, JEOL 1200 EX, Tokyo, Japan) and dynamic 
light scattering (DLS; ZetaPals, Brookhaven 
Instrument, Holtsville, NY). To prepare samples for 
TEM, a drop of nanoparticle solution was put on the 
surface of a Formvar coated 200-mesh copper grid 
(Electron Microscopy Sciences, Hatfield, PA) and 
air-dried before loading onto a microscope. For DLS, 1 
mg/ml nanoparticle solution was directly added to a 
cuvette for size, polydispersity and surface charge 
measurements. Next, Fourier transform infrared 
spectroscopy (FTIR; Nicolet 6700 FT-IR spectrometer, 
Thermo Fisher Scientific, Madison, WI) was 
performed to analyze characteristic peaks associated 
with the chemical bonds in the polymer chain. All 
FTIR samples were purified, lyophilized powders. 
The LCST of the TFP NPs was also determined 
quantitatively by heating the nanoparticle solution in 
1°C increments from room temperature up to 45°C in 
a glass cuvette, and by measuring the absorbance of 
the nanoparticle solution at 500 nm wavelength using 
Nanotheranostics 2020, Vol. 4 
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UV-Vis spectrophotometry (Biorad, SmartSpec Plus, 
Life Science Research, Hercules, CA). 
Nanoparticle stability and degradation were 
studied at physiological conditions. To study particle 
stability, the TFP-MNPs were incubated in phosphate 
buffered saline (PBS) or 10% FBS solution at 37°C and 
the particle size was measured up to 72 hours using 
DLS. To study the degradation of the TFP shell, 
TFP-MNPs were suspended in DI water and 
incubated at 37°C over a period of time. At each time 
point, nanoparticles were collected by a magnet, and 
dry weight of the nanoparticles was recorded. A 
relative percentage of dry weights of the 
nanoparticles at all the time points were calculated 
with respect to the initial dry weight of the 
nanoparticles. 
Magnetic characterization 
The iron content in the nanoparticles was 
evaluated using iron assays as described previously 
[24]. Briefly, 100 µl of the nanoparticle solution was 
incubated with 50% (v/v) hydrochloric acid at 37°C 
overnight. Subsequently, APS solution (1 mg/ml) and 
0.1 M potassium thiocyanate solution were added 
with 15 minutes incubation between each step. The 
absorbance readings of the samples were taken at 520 
nm using a UV-Vis spectrophotometer (Infinite M200 
plate reader, Tecan, Durham, NC). Additionally, 
magnetic recruitment of the TFP-MNPs were tested in 
the presence of an external magnet and compared 
with the TFP-MNPs suspension in the absence of the 
external magnet. 
The magnetic properties of TFP-MNPs were 
analyzed using a vibrating sample magnetometer 
(VSM, KLA-Tencor EV7, San Jose, CA) and compared 
to those of bare MNPs. The samples consisting of 
equal amounts of iron were embedded in wax and 
hysteresis loops were obtained by varying the 
magnetic fields at room temperature. Then MR 
imaging was done on agarose phantoms containing 
varying concentrations of TFP-MNPs (0, 0.25, 0.5, 1 
and 2 mg/ml). Agarose phantoms containing TFP 
NPs (without MNPs) were imaged as negative 
control. T2 weighted images were acquired using TR: 
2500 ms, TE: 10 ms, FOV: 40x40 mm, and with a slice 
thickness of 1 mm. 
Fluorescence characterization 
The fluorescence from the nanoparticles was 
observed in UV light. The positive control contained 
WBPLP solution and the negative control contained 
PNIPAAm-AH solution. Furthermore, the effect of 
temperature on the fluorescence intensity of the 
nanoparticles was investigated. Briefly, the TFP NPs 
(3 mg/ml) in a tube were immersed in a water tank 
that was heated using a temperature controller. The 
sample was excited with a blue laser (473 nm) and the 
emitted light was passed through a 532 nm long pass 
filter. The fluorescence intensity was recorded as 
voltage read out from a high-speed digital 
oscilloscope. The measurements were taken at 
temperatures ranging from 25°C to 45°C with an 
increase of 0.5°C. The fluorescence intensities of these 
measurements were then converted to the percentage 
lost in the fluorescence intensity as a function of 
temperature. 
Drug loading and release 
For drug loading and release studies, 
hydrophilic doxorubicin hydrochloride (Dox; Tocris 
Bioscience, Ellisville, MO) was used as an anti-cancer 
drug model. Freeze-dried TFP-MNPs (10 mg) were 
suspended in Dox (0.02% w/v in PBS) solution and 
incubated at 4°C for 3 days, with gentle stirring to 
allow loading of the drug into the nanoparticles by 
virtue of the drug absorption via polymer swelling at 
low temperatures. After 3 days, the Dox-loaded 
TFP-MNPs (Dox-TFP-MNPs) were separated using a 
magnet (1.3 T) and the supernatant was collected to 
determine the Dox encapsulation efficiency using the 
following formula: Encapsulation efficiency (%)= (Initial drug amount − Supernatant drug amount)Initial drug amount ∗ 100 
To study thermo-responsive drug release, the 
Dox-TFP-MNPs were incubated at 25°C (room 
temperature, < LCST), 37°C (physiological 
temperature, < LCST), or 41°C (> LCST) in PBS. At 
predetermined time points, an external magnet was 
used to separate the nanoparticles in each of the three 
groups, and 1 ml of the supernatant was collected. 
The same volume was replenished with fresh PBS. 
Dox concentrations in the collected samples were 
measured by UV-Vis spectrofluorometer at 470 nm 
excitation and 585 nm emission wavelengths and 
calculated using a Dox standard curve. 
In vitro cell studies 
For cytocompatibility studies, human dermal 
fibroblasts (HDFs) and normal prostate epithelial cells 
(PZ-HPV-7) were seeded in a 96-well plate at a 
density of 5000 cells/well and maintained at 37°C and 
5% CO2 for 24 hours. The culture medium was 
replaced with media containing increasing 
concentrations of TFP-MNPs (0, 50, 100, 200, 300, and 
500 µg/ml) and the cells were incubated for 12 and 24 
hours. Cells exposed to media only served as positive 
controls. The cell viability was determined at each 
time point using cell viability MTS assays (CellTiter 96 
Nanotheranostics 2020, Vol. 4 
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Aqueous One Solution Cell Proliferation Assay, 
Promega, Madison, WI) following the manufacturer’s 
instructions. 
Cellular uptake of nanoparticles was studied on 
A431 and G361 skin cancer cells as well as on PC3 and 
LNCaP prostate cancer cells. First, the cells were 
seeded in a 96-well plate as described earlier. 
Following overnight incubation at 37°C, the media 
was replaced with different concentrations of 
TFP-MNPs (0, 50, 100, 200, 300, and 500 µg/ml) 
prepared in RPMI-1640 and the well plate was 
incubated for 2 hours. Cells that were not exposed to 
nanoparticles served as controls. Following 
incubation, the cells were washed with PBS three 
times and then lysed using 1X Triton. The contents in 
the wells were then analyzed using iron assay and 
Picogreen DNA assay (Invitrogen, Carlsbad, CA) to 
quantify the nanoparticle amount and cell protein 
content per well. 
For cancer cell killing studies, skin cancer cells 
(A431, G361) and prostate cancer cells (PC3) were 
seeded at a density of 5000 cells/well in 96-well plates 
and incubated overnight at 37°C to facilitate cell 
attachment. The following day, the cell media was 
aspirated, and the cells were treated with media only, 
free Dox, Dox-TFP-MNPs or empty TFP-MNPs. Free 
Dox was dosed at the IC50 value of the drug with 
respect to each of the cell lines (37 nM for A431, 32 nM 
for G361, and 258 nM for PC3 cells). The dose of 
Dox-TFP-MNPs was then calculated as the 
concentration of nanoparticles which would release a 
cumulative IC50 dose of Dox in 24 hours. The empty 
TFP-MNPs were dosed at the same concentration as 
Dox-TFP-MNPs. The treated cells were incubated at 
37°C or 41°C for 24 hours. The cell viability was then 
quantified by MTS assays. 
In vivo animal studies 
All in vivo studies were conducted in compliance 
with the guidelines set by the University of Texas at 
Arlington and the University of Texas Southwestern 
Institutional Animal Care and Use Committees. NOD 
SCID mice (6-8 weeks old males) purchased from the 
University of Texas Southwestern mouse breeding 
core were used for in vivo studies. Prostate cancer 
xenograft models were developed by injecting 
subcutaneously into both flanks of the animal, DAB2 
interactive protein knockdown (KD) prostate cancer 
cells (PC3-KD) (~5x105 cells/site), as described 
elsewhere [25]. The mice were observed periodically, 
and the experiments were performed when the 
tumors were palpable. 
For fluorescence imaging, BPLP-MNPs (100 μl of 
5 mg Fe/kg), TFP-MNPs (100 μl of 5 mg Fe/kg), or 
TFP NPs (100 μl of 3 mg/ml) were injected 
intra-tumorally. BPLP-MNPs were used as control 
nanoparticles and were synthesized as described 
elsewhere [7]. The flank tumors were then imaged 
using an in vivo Kodak imaging system (Carestream 
Health Inc., Rochester, NY). The relative fluorescence 
intensity from the tumors injected with nanoparticles 
was calculated by subtracting the fluorescence 
intensity of the tumors that were not injected with the 
nanoparticles. 
For MRI studies, a baseline MRI was obtained on 
flank tumors by T2 weighted imaging (TR = 2500 ms, 
TEeff = 60 ms, FOV = 40x40 mm, slice thickness = 1 
mm). Then saline and TFP-MNPs (1 mg) with or 
without magnetic targeting were injected via the tail 
vein and MR images were taken 24 hours later. The 
difference in MRI signal intensity between the groups 
was then analyzed using Image J. 
For in vivo therapeutic efficacy study, C57BL6 
mice were injected with B16F10 skin cancer cells in the 
flanks. When the tumors grew 8-10 mm3 in volume, 
saline, free Dox (40 µg/ml, 200 µl), empty TFP-MNPs 
(0.8 mg/ml, 200 µl) or Dox-TFP-MNPs (0.8 mg/ml, 
200 µl) were intravenously injected. The animals were 
then placed on a heating pad at 37°C for 30 min with a 
1.3 T magnet placed near the tumors to magnetically 
recruit nanoparticles in the region. The animals were 
then allowed to return to their cages. At each 
predetermined time point, the tumor volumes were 
measured using Vernier caliper. On day 15, the 
surviving animals were sacrificed and the tumor 
volumes were recorded. 
Statistical analysis 
The results obtained were analyzed using 
one-way analysis of variance with p < 0.05 and post 
hoc comparisons. All the experiments were repeated 
multiple (at least two) times with a sample size of four 
(n=4). All the results were presented as 
mean ± standard deviation if not specified. 
Results 
Physicochemical characterization 
The copolymerization of WBPLP-AH and 
PNIPAAM, and their incorporation into the TFP NPs 
and TFP-MNPs was confirmed via FTIR analysis 
(Figure 1A). The FTIR spectrum of NIPAAm showed 
characteristic peaks corresponding to C=O (1730 cm-1) 
and N-C=O (1590 cm-1) bonds. WBPLP-AH spectrum 
had peaks corresponding to CH2 (3015 cm-1), -OH 
stretching (3496.2 cm-1) and CO-NH (1704 cm-1) bond, 
which confirmed the successful conjugation of AH to 
the WBPLP. The FTIR spectrum of TFP NPs retained 
the peaks corresponding to CH2 groups (3010 cm-1) 
from WBPLP-AH and CO-NH (1635 cm-1) and C=O 
Nanotheranostics 2020, Vol. 4 
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(1705 cm-1) bonds from NIPAAm. The TFP-MNPs 
spectrum also showed the presence of these bonds in 
addition to the Fe3O4 (540 cm-1) peak, confirming the 
incorporation of MNPs. These findings were in 
agreement with our previous observations confirming 
the presence of MNPs [10] and all the corresponding 
bonds from WBPLP and PNIPAAm coatings [5, 26]. 
Hydrodynamic diameter, PDI and ζ potential of 
the TFP NPs was ~150 nm, 0.28 and -13.4 mV, 
respectively while that of TFP-MNPs was ~135 nm, 
0.07 and -31.0 mV, respectively (Table 1). The TEM 
images showed MNPs as dark circular particles and 
the TFP NPs appeared as lighter polymeric particles 
(Figure 1B). The TFP-MNPs showed a dark magnetic 
core and a lighter polymeric shell in their structure. 
Stability studies indicate that the TFP-MNPs varied by 
less than 15 % of their original size in PBS and 10% 
FBS solution at 37°C over a period of 72 hours (Figure 
1C). These results indicate that the nanoparticles are 
stable and would likely not aggregate under 
physiological conditions. Furthermore, the phase 
transition behavior of TFP NPs was characterized by 
measuring absorbance (λmax = 500 nm) of the 
nanoparticle solutions at each unit increment in 
temperature using a UV-Vis spectrophotometer. The 
LCST of the nanoparticles (39°C) was evaluated at the 
solution temperature where the transmittance drops 
to 50% of initial value (Figure 1D). At temperatures 
below LCST, the polymer was hydrophilic, making 
the solution clear. The solution turned turbid when 
the polymer became hydrophobic at temperatures 
equal to or greater than the LCST. This result confirms 
the thermo-responsive behavior of TFP NPs even after 
copolymerization of PNIPAAm with AH and WBPLP. 
 
 
Figure 1: Physicochemical characterization of nanoparticles. (A) FTIR spectra of TFP-MNPs, TFP NPs, WBPLP-AH and NIPAAm with arrows indicating the 
peaks associated with bonds in polymer backbone and MNPs. (B) TEM images of MNPs, TFP NPs, and TFP-MNPs (all scale bars = 100 nm). (C) Stability of TFP-MNPs 
in PBS and 10% FBS at 37°C for 72 hours as measured by changes in nanoparticle size. (D) Phase transition of TFP NPs at LCST (39°C). (E) Temperature-dependent 
Dox release kinetics showing higher release at 41°C compared to 37°C and 25°C. (F) Degradation profile of TFP shell on MNPs core showing 86% polymer weight 
loss in 13 days. 
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Figure 2: Magnetic properties of nanoparticles. (A) Photographs showing TFP-MNPs suspension in water (left) and recruitment of TFP-MNPs towards a 1.3 
T magnet (right). (B) Hysteresis loops of bare MNPs and TFP-MNPs followed the same trend demonstrating their superparamagnetic behavior. (C) T2 weighted MR 
images of agarose phantoms containing i. agarose only, ii. TFP NPs, and iii-vi. TFP-MNPs at 0.25, 0.5, 1, and 2 mg/ml concentrations, respectively, showing increasing 
negative contrast with increasing iron oxide concentration in agarose phantoms. 
 
Table 1: Physicochemical characterization of nanoparticles 
Sample Diameter (nm) PDI ζ Potential (mV) Iron (%) 
MNPs 10a 0.30 -5.1 100 
Silane-MNPs 18b 0.35 -21.0 __ 
TFP NPs 150 0.28 -13.4 __ 
TFP-MNPs 135 0.07 -31.0 75 
aSize provided by the supplier 
bSize obtained from TEM analysis (image not shown) 
 
 
Dox loading efficiency in TFP-MNPs was ~90%, 
which was higher in comparison to the Dox loading 
efficacy in previously synthesized PNIPAAm-AAm- 
AH-based MNPs (82%) by our group. The higher 
loading of Dox in TFP-MNPs might be due to either 
the interaction between Dox and TFP or more 
polymeric swelling of TFP at temperatures below the 
LCST while loading Dox. A temperature-dependent 
biphasic Dox release was observed (Figure 1E). Dox 
was released in a significantly higher amount at 41°C 
(temperature > LCST of TFP) compared to that of 
37°C and 25°C. There was no difference between Dox 
release at 37°C and 25°C, as both the temperatures 
were below the LCST of TFP. Since drug release can 
also be caused by degradation of the polymer shell, 
degradation of the TFP coating on MNPs in DI water 
was studied over time. It was observed that the 
TFP-MNPs lost 31% polymer weight during the first 4 
days (Figure 1F). The degradation rate was then 
reduced, which resulted in 37% polymer weight loss 
over 13 days. The reduction in the degradation rate 
was due to the presence of PNIPAAm and AH 
slowing down the hydrolysis of the WBPLP. It is 
speculated that the TFP degradation will take longer 
than that of WBPLP alone. 
Magnetic characterization 
The TFP-MNPs were comprised of 
approximately 75% mass of iron (Table 1). Moreover, 
in the absence of a magnet, nanoparticles were 
suspended and well-dispersed in DI water (Figure 
2A). While in the presence of a 1.3 T magnet, 
nanoparticles concentrated toward the magnet, 
demonstrating the recruitment of nanoparticles via 
magnetic targeting. VSM results indicate that the iron 
oxide within TFP-MNPs retained their 
superparamagnetic properties and showed a similar 
hysteresis loop as bare MNPs (Figure 2B). The 
saturation magnetization for bare MNPs and 
TFP-MNPs was 63 and 46 emu/g, respectively. A 
remanence and coercivity of 6.24 (Mr/Ms) and 59.9 
Oe, respectively, was quantified for the TFP-MNPs, 
while bare MNPs had a remanence of 8.16 (Mr/Ms) 
and coercivity of 75.5 Oe. In addition, agarose 
phantoms containing these particles produced a 
distinct negative contrast in MRI with greater 
negative contrast observed with increasing 
concentration of the particles (Figure 2C). These 
observations show that the TFP-MNPs possess strong 
magnetic properties as well as can potentially act as 
MRI contrast agents. 
Fluorescence properties 
Samples of PNIPAAm-AH, WBPLP, and TFP 
NPs were subjected to natural light and UV 
illumination in dark. There was no fluorescence from 
any of the samples in white light (Figure 3A). 
However, a bright fluorescence was observed from 
WBPLP and TFP nanoparticles under UV 
illumination. The negative control PNIPAAm-AH did 
not display any fluorescence contrary to TFP NPs, 
which demonstrated fluorescence under UV 
illumination, suggesting the origins of TFP NP 
fluorescence from WBPLP. Furthermore, a 
temperature-dependent fluorescence study was 
performed. The mean fluorescence intensity of TFP 
remained the same with increasing temperature 
(Figure 3B). The fluorescence photobleaching effect 
was also tested at 23°C and 46°C. Even after more 
than 10 minutes of continuous laser excitation, no 
photobleaching was observed and the fluorescence 
intensity remained stable. This indicates that the 
fluorescence of the TFP-MNPs will not be affected by 
temperature changes. 
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Figure 3: Characterization of fluorescence property. (A) Photographs of PNIPAAm-AH, WBPLP and TFP NPs samples in ambient white light and UV light. (B) 
Fluorescence intensity of TFP NPs was measured at increasing temperatures and plotted as fluorescence intensity lost as a function of temperature. 
 
In vitro cell studies 
Cytocompatibility of TFP-MNPs was tested on 
HDFs and PZ-HPV-7 cells. It was observed that the 
TFP-MNPs were not toxic at the tested concentrations 
for both cell types after 12 hours of incubation (Figure 
4A-B). However, after 24 hours of exposure, the 
TFP-MNPs showed some level of toxicity towards 
HDFs, 27% cell death at 500 µg/ml concentration 
compared to the controls. The particles were more 
compatible with the PZ-HPV-7 cells, about 12% and 
18% cell death was observed at 300 and 500 µg/ml 
concentrations, respectively. PZ-HPV-7 cell viability 
was above 80% at all concentrations of TFP-MNPs. 
The uptake of TFP-MNPs by A431 and G361 skin 
cancer cells and LNCaP and PC3 prostate cancer cells 
was investigated. A dose-dependent uptake of the 
particles was observed in all cancer cell lines 
following 2 hours of incubation with the particles 
(Figure 4C-D). Higher uptake of TFP-MNPs was seen 
in skin cancer cells especially at higher concentrations. 
Furthermore, uptake seemed to saturate between 
200-300 µg/ml TFP-MNPs concentration in the case of 
all the cell lines. 
A cancer cell killing study was performed to 
determine the in vitro therapeutic efficacy of 
Dox-TFP-MNPs with changes in temperature. It could 
be seen clearly that in the case of all the cell lines 
(A431, G361, PC3) treated with Dox-TFP-MNPs, 
greater cell death was observed at 41°C (about 31%, 
32% and 44% cell viability, respectively) compared to 
the cell death at 37°C (about 83%, 82% and 77% cell 
viability, respectively) (Figure 4E). About 30% of the 
cell death at 41°C could be attributed to hyperthermia 
as seen in the case of the control groups at 41°C. 
Minimal cell death was observed on exposure of the 
cell lines to empty TFP-MNPs. 
In vivo imaging and therapeutic efficacy 
In vivo fluorescence imaging was performed after 
intra-tumoral injections of nanoparticles. The control 
tumors (without nanoparticle injections) did not 
display any fluorescence (Figure 5A). A bright 
fluorescence was detected from the tumors injected 
with TFP NPs, which was then reduced significantly 
for TFP-MNPs due to the presence of darker MNPs 
(Figure 5B). However, the fluorescence intensity from 
TFP-MNPs was significantly higher than that of 
hydrophobic BPLP-MNPs. These results show that 
the TFP-MNPs can overcome the limitation of 
reduced fluorescence from our previously developed 
BPLP-MNPs [7]. 
Magnetic targeting and in vivo MR imaging 
Tumor bearing mice were injected with 
TFP-MNPs via tail vein injections and the localization 
of the nanoparticles was studied in the presence or 
absence of a 1.3 T magnetic field. The tumors in both 
the magnetic and non-magnetic field treated group 
were imaged before and 24 hours post injection. A 
negative contrast was observed in the tumors of mice 
injected with TFP-MNPs and subsequently treated 
with a localized magnetic field, indicating that the 
particles were able to be recruited at the tumor site 
(Figure 5C). TFP-MNPs administered animals without 
the localized magnetic field treatment did not have 
any significant darkening in the tumor region. 
Analysis of the signal intensity values of the tumors 
showed a significant drop (~21%) in signal intensity 
in animals injected with TFP-MNPs in the presence of 
localized magnetic fields (Figure 5D). The controls 
and the groups treated with TFP-MNPs in the absence 
of magnetic targeting showed signal intensity drops 
of 3.8% and 8.2%, respectively. 
In vivo therapeutic efficacy 
In vivo therapeutic efficacy of Dox-TFP-MNPs 
was studied in animals implanted with B16F10 skin 
tumors in the presence of a 1.3 T magnetic field. At the 
end of the 15-day study, only an 11-fold increase in 
the original tumor volume was observed in animals 
treated with Dox-TFP-MNPs in the presence of the 
magnetic field (Figure 6). On the other hand, the 
control animals given saline injections showed a 
61-fold increase in their original tumor volumes. The 
animals in the empty TFP-MNPs and free Dox group 
showed 59-fold and 21-fold increases in their tumor 
volumes, respectively. 
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Figure 4: In vitro cytocompatibility, cellular uptake, and therapeutic efficacy of nanoparticles. (A) Cytocompatibility profiles of TFP-MNPs in normal 
human dermal fibroblasts (HDFs) and (B) normal prostate epithelial cells (PZ-HPV-7) as measured by MTS assays. (C) Cellular uptake profiles of TFP-MNPs on LNCaP 
and PC3 prostate cancer cells and (D) A431 and G360 skin cancer cells. (E) Cytotoxicity of nanoparticles on skin cancer (A431, G361) and prostate cancer (PC3) cells 
at 37°C and 41°C as measured by MTS assays. *p < 0.05. 
 
Discussion 
Advancements in cancer diagnosis, treatment 
and preventative approaches have led to a drop in 
cancer mortality rates, showing marginal 
improvements in survival. Although chemotherapy 
has been successful in reducing cancer related deaths, 
it often has poor pharmacokinetic profiles in addition 
to nonspecific toxicity. Nanoparticle mediated drug 
delivery of chemotherapeutics potentially seeks to 
eliminate these limitations and have improved 
survival outcomes with many clinically developed 
nanoparticulate systems demonstrating reduced 
systemic toxicity, albeit they have yet to succeed in 
improving long-term survival. This warrants the 
development of newer nanoscale systems with 
improved functionalities and additions of 
multifunctionality into the nanoparticle design. With 
the goal to develop a degradable PNIPAAm-based 
theranostic drug delivery system, we investigated the 
synthesis and characterization of biodegradable TFP 
NPs and a core-shell system containing a magnetic 
core and TFP shell (TFP-MNPs). 
Physicochemical characterization of our 
nanoparticles showed well formulated nanoparticles 
with excellent colloidal stability in physiological 
conditions. The negative surface charges of the 
TFP-MNPs potentially repel negatively charged 
albumin molecules in the serum, preventing 
agglutination mediated aggregation [27]. 
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Furthermore, TFP holds the unique characteristics of 
thermo-responsiveness from PNIPAAm as well as 
fluorescence and degradability from WBPLP. The 
increase in LCST (39°C) of the copolymeric 
nanoparticles compared to PNIPAAm nanoparticles 
(LCST = ⁓32-34°C) can be attributed to the 
incorporation of hydrophilic WBPLP-AH [11, 15]. The 
sharp volume phase transition of the nanoparticles is 
advantageous, enabling a burst release of drugs 
followed by a more sustained release, especially at 
41°C. The degradation of the polymer shell was 
mainly due to hydrolysis of WBPLP, eventually 
breaking down PNIPAAm into smaller fragments that 
can be potentially cleared in vivo. Interestingly, the 
fluorescence from WBPLP was well preserved in the 
new copolymer even at higher temperatures. In 
addition, incorporating MNPs into the TFP NPs has 
added advantages of magnetic targeting as well as 
using these particles as MRI contrast agents. TFP 
coating did not affect the superparamagnetic behavior 
of MNPs. A small decrease in the saturation 
magnetization of TFP-MNPs compared to bare MNPs 
can be attributed to the diamagnetic moment of the 
polymeric coating [23]. Similar PNIPAAm 
copolymeric systems grafted on MNPs have been 
shown to have a slight decrease in saturation 
magnetization, which has been attributed to the 
grafting of polymers to the iron oxide core [28]. The 
presence of an iron oxide magnetic core in TFP-MNPs 
renders them the ability to dephase proton spins 
causing a reduction in MR signal intensity, making 
them useful as T2 contrast agents [29]. 
 
 
Figure 5: In vivo imaging and magnetic targeting of nanoparticles. (A) Fluorescent images of prostate cancer tumors in mice after intra-tumoral injection of 
nanoparticles. (B) Relative fluorescence intensities from the panel A (*p < 0.05). (C) T2-weighted MR images of prostate tumors in mice before and 24 hours after i.v. 
injection of nanoparticles in the presence or absence of an external magnet. The red arrow indicates negative contrast generated due to accumulation of TFP-MNPs. 
(D) MRI signal intensity drop in prostate cancer tumors 24 hours post-injection from the panel C (*p < 0.05). 
 
Figure 6: In vivo therapeutic efficacy of nanoparticles. Skin cancer B16F10 tumor volume fold increase in mice after i.v. injection of nanoparticles in the 
presence of 1.3 T external magnet (*p < 0.05). 
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Overall, in vitro data including cell studies 
further highlights the potential of TFP-MNPs as a 
drug delivery vehicle for solid tumors. Surface 
properties of nanoparticles play a major role in 
cellular toxicity and uptake. The negatively charged 
polymer shell is potentially alleviating 
MNP-mediated toxicity [30, 31] by preventing MNP 
interactions with the cell membrane. Further, the 
differential uptake of TFP-MNPs in prostate and skin 
cancer cells is in agreement with our previous studies 
on the uptake of BPLP-MNPs and WBPLP-MNPs in 
PC3 and LNCaP cell lines where the more hydrophilic 
WBPLP-MNPs showed significant preferential uptake 
into PC3 cell lines relative to LNCaP cell lines [7]. It 
has been shown that MNPs coated with proteins 
exhibited preferential cellular uptake in different 
cancer cell lines, even in isogenic cell lines [32]. The 
preferential uptake of TFP-MNPs by PC3 and G361 
cancer cell lines, which have higher metastatic 
potential than LNCaP and A431 cell lines, indicates 
the utility of TFP-MNPs to target more aggressive 
kinds of cancers [33]. Further, Dox-TFP-MNPs were 
effective in killing cancer cells under simulated 
hyperthermia conditions. The insignificant difference 
in cell killing between free Dox and Dox-TFP-MNPs at 
41°C across all cell lines was potentially due to the fact 
that free Dox experiences increased cellular uptake at 
temperatures exceeding 40°C as well as has the ability 
to be actively cytotoxic without entering cells [34, 35]. 
The cell death in untreated controls and empty 
TFP-MNPs group at 41°C was attributed to the 
negative effects of hyperthermia [36, 37]. 
Our preliminary in vivo data showed the 
dual-imaging, magnetic targeting, and therapeutic 
efficacy potential of the TFP-MNPs. A significantly 
higher fluorescent intensity in TFP NPs treated 
groups compared to TFP-MNPs was possibly due to 
the presence of a darker iron oxide core, which has 
been shown to quench fluorescence on contact with 
various fluorescent materials [38-40]. The quenching 
of fluorescence was quantitatively lesser in 
TFP-MNPs compared to MNPs coated with the 
fluorescent hydrophobic BPLP polymer. We believe 
this difference is due to the nature of the polymer 
interaction with the MNP surface. The covalent 
bonding of TFP to the MNPs holds the polymer shell 
in place compared to the physical adsorption of BPLP 
on the MNP surface, increasing the possibility of 
BPLP shell/fragments separating from MNPs. 
Further, magnetic targeting played a key role in 
recruiting TFP-MNPs at the tumor site in sufficient 
doses to be therapeutically effective. The use of 
magnetic targeting to deliver drugs to tumors relies 
on the physical force of magnetic fields to partition 
the magnetic carrier from the arteriole wall into the 
tumor region resulting in increased drug localization 
and retention even after the subsequent removal of 
the applied magnetic field [18, 41]. Similar drug 
carrying magnetic nanocarriers using magnetic 
targeting have been shown effective in delivering 
various agents like mitoxantrone, epirubicin and 
doxorubicin in tumor bearing rats and cause tumor 
remission in various cancer models [42-44]. 
Our study has a few limitations. We have used 
different cell lines from two different cancer types for 
in vitro experiments and two different animal models 
for in vivo experiments. While our TFP-MNPs are not 
tested extensively on one particular disease, we 
intended to show the theranostic feasibility and 
effectiveness of our nanoparticles on different solid 
tumor types. In addition, in the current age of active 
(receptor-mediated) targeting of nanoparticles, our 
nanoparticle design lacks this advantageous element. 
In the future, we plan to conjugate TFP-MNPs with 
targeting moieties and cell penetrating peptides, 
giving the nanoparticle system specificity towards 
solid tumors and explore a targeted site-specific 
delivery. Nonetheless, we could show the 
effectiveness of TFP-MNPs in controlling tumor 
growth by using magnetic targeting as a standalone 
approach. Our results demonstrated a great potential 
of TFP-MNPs as a theranostic platform technology. 
The development of TFP-MNPs will not only 
overcome the drawbacks of the long-term toxicity of 
quantum dots and poor photostability of organic 
dyes, but also allow simultaneous diagnosis and 
treatment of cancers in a single setting. In the future, 
these nanoparticles with the use of alternating 
magnetic fields, could be used for producing heat for 
hyperthermia therapy and temperature-controlled 
drug release, enabling combinational treatment 
options [23, 24]. Therefore, we think that TFP-MNPs 
can serve as an effective platform for future 
development of theranostic nanoparticles. 
Conclusion 
We developed a novel TFP and its core-shell 
structure with magnetic nanoparticles - TFP-MNPs. 
TFP-MNPs maintained excellent colloidal stability 
and had a degradable shell that eliminates long-term 
toxicity concerns and bypasses the size limitations for 
in vivo clearance in the traditional nanoparticle 
designs. The thermo-responsiveness of the 
PNIPAAm-AH was preserved after copolymerization 
with WBPLP to form TFP. The imaging studies 
showed optical and MR imaging capabilities using 
TFP-MNPs. Finally, the cytocompatible nanoparticles 
magnetically recruited to the tumor region delivered 
therapeutic doses of doxorubicin to inhibit tumor 
growth. We showed multifunctional capabilities of 
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TFP-MNPs including multimodal imaging, magnetic 
targeting, and thermo-responsive drug release, 
making TFP-MNPs an excellent platform of 
theranostic systems for future cancer diagnosis and 
therapy. 
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